| Q34423486 | A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease |
| Q38805718 | A Comprehensive Overview of the Hereditary Periodic Fever Syndromes |
| Q99240141 | A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges |
| Q33622218 | A case of cryopyrin-associated periodic syndrome with kidney transplant failure |
| Q90289994 | A case report of locally invasive Aspergillus fumigatus infection in a patient on canakinumab |
| Q37869439 | A clinical perspective of IL-1β as the gatekeeper of inflammation |
| Q34632661 | A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. |
| Q27687429 | A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. |
| Q38633441 | A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis |
| Q38773387 | A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner |
| Q84100413 | Accelerate medical breakthroughs by ending disease earmarks |
| Q84801790 | Acute inflammatory arthritis: interleukin-1 blockade: a magic wand for gout? |
| Q39016299 | An Update on the Use of Immunomodulators in Primary Immunodeficiencies |
| Q34254955 | An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome |
| Q35219001 | An expanding role for interleukin-1 blockade from gout to cancer |
| Q64110826 | An innate interaction between IL-18 and the propeptide that inactivates its precursor form |
| Q59136398 | Anakinra Therapy for Non-cancer Inflammatory Diseases |
| Q38993312 | Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes |
| Q37277309 | Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology |
| Q38168948 | Anakinra for cryopyrin-associated periodic syndrome |
| Q40852651 | Analysis of clinical trials with biologics using dose-time-response models |
| Q27495968 | Anti-Interleukin-1 Agents in Adult Onset Still's Disease |
| Q37118156 | Anti-inflammatory Agents: Present and Future |
| Q55293840 | Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients. |
| Q51722492 | Applying physiological and biochemical concepts to optimize biological drug development. |
| Q38085854 | Autoinflammation: From monogenic syndromes to common skin diseases |
| Q34369278 | Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses |
| Q35558406 | Autoinflammation: translating mechanism to therapy |
| Q37048084 | Autoinflammatory Skin Disorders: The Inflammasomme in Focus |
| Q38715104 | Autoinflammatory Syndromes in Children |
| Q36520994 | Autoinflammatory disease reloaded: a clinical perspective |
| Q40376307 | Autoinflammatory diseases in childhood |
| Q40153519 | Autoinflammatory syndromes as causes of fever of unknown origin |
| Q40326095 | Autoinflammatory syndromes/fever syndromes |
| Q37784856 | Autoinflammatory syndromes: diagnosis and management |
| Q34135558 | Averting inflammation by targeting the cytokine environment |
| Q27011650 | Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence |
| Q38060204 | Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics |
| Q37887422 | Biologic modulators in allergic and autoinflammatory diseases |
| Q37077564 | Biological treatments: new weapons in the management of monogenic autoinflammatory disorders |
| Q39084627 | Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. |
| Q37765830 | Biologics in children's autoimmune disorders: efficacy and safety |
| Q37696271 | Blockade of interleukin 1 in type 1 diabetes mellitus |
| Q34822708 | Blocking interleukin-1 in rheumatic diseases |
| Q37821071 | Blocking interleukin-1β in acute and chronic autoinflammatory diseases |
| Q48088115 | Bone involvement in monogenic autoinflammatory syndromes |
| Q36702456 | Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics |
| Q54237287 | CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis. |
| Q38473823 | CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease |
| Q24642193 | Canakinumab |
| Q35620372 | Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS) |
| Q35535362 | Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment |
| Q54806476 | Canakinumab for the cryopyrin-associated periodic syndromes |
| Q38814103 | Canakinumab for the treatment of TNF-receptor associated periodic syndrome |
| Q40199493 | Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study |
| Q38865019 | Canakinumab for the treatment of familial Mediterranean fever. |
| Q38255582 | Canakinumab for the treatment of systemic juvenile idiopathic arthritis |
| Q37800938 | Canakinumab for treatment of cryopyrin-associated periodic syndrome |
| Q40427207 | Canakinumab in adults with steroid-refractory pyoderma gangrenosum. |
| Q37331996 | Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians |
| Q38085662 | Canakinumab in pediatric rheumatic diseases |
| Q35012174 | Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study |
| Q35092969 | Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study |
| Q98648527 | Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study) |
| Q37604504 | Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study |
| Q54806474 | Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes |
| Q37968285 | Canakinumab: in patients with cryopyrin-associated periodic syndromes |
| Q34336335 | Caspase functions in cell death and disease |
| Q89526718 | Caspases in Cell Death, Inflammation, and Gasdermin-Induced Pyroptosis |
| Q92665944 | Cell death-mediated cytokine release and its therapeutic implications |
| Q40231494 | Challenges in diagnosing Muckle-Wells syndrome: identifying two distinct phenotypes |
| Q28066948 | Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review |
| Q35928265 | Chronic inflammation in cancer development. |
| Q37942581 | Clinical and biochemical landmarks in systemic autoinflammatory diseases |
| Q40049062 | Clinical and molecular phenotypes of low-penetrance variants in NLRP3: Diagnostic and therapeutic challenges |
| Q42075063 | Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis |
| Q36903004 | Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature |
| Q37026106 | Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? |
| Q37986236 | Cold-induced urticaria with a familial transmission: a case report and review of the literature |
| Q35886682 | Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain |
| Q50051013 | Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes. |
| Q89746290 | Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative |
| Q33673719 | Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta |
| Q38845570 | Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? |
| Q43701983 | Corneal response to canakinumab in cryopyrin associated periodic fever syndrome |
| Q40356964 | Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). |
| Q36137849 | Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the nlrp3 protein |
| Q40289375 | Cryopyrin-associated periodic syndrome |
| Q51533520 | Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement |
| Q37811988 | Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response |
| Q37688957 | Cryopyrin-associated periodic syndromes: background and therapeutics |
| Q37984096 | Cryopyrin-associated periodic syndromes: diagnosis and management |
| Q97521410 | Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide |
| Q27693189 | Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation |
| Q93095137 | Current perspectives on the interleukin-1 family as targets for inflammatory disease |
| Q37871438 | Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. |
| Q38574807 | Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome |
| Q93158334 | Cytokine Circuits in Cardiovascular Disease |
| Q37875779 | Danger signals activating innate immunity in graft-versus-host disease |
| Q34212591 | Deregulated inflammasome signaling in disease |
| Q45772071 | Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties |
| Q37496388 | Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013 |
| Q34623105 | Development trends for human monoclonal antibody therapeutics |
| Q40210237 | Diagnostic validity of colchicine in patients with Familial Mediterranean fever |
| Q37919837 | Does this patient have periodic fever syndrome? |
| Q64042641 | Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes |
| Q36250852 | Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab |
| Q58594489 | Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene |
| Q37602644 | Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy |
| Q27303524 | Early detection of sensorineural hearing loss in Muckle-Wells-syndrome |
| Q51355147 | Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. |
| Q40051587 | Effects of Anakinra on Health-Related Quality of Life in a Patient with 1129G>A/928G>A Mutations in MVK Gene and Heterozygosity for the Mutation 2107C>A in CIAS1 Gene |
| Q40053587 | Efficacy and safety analysis of off-label treatment with biologics in autoinflammatory diseases : Experiences from a German registry (GRAID2) |
| Q36027314 | Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever |
| Q45325652 | Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. |
| Q33953931 | Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study |
| Q40287066 | Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study |
| Q36798016 | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature |
| Q49071287 | Emerging inflammasome effector mechanisms |
| Q54316388 | Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. |
| Q62658633 | Etiopatogenia de los síndromes asociados a criopirina: genética, bases moleculares y el inflamasoma |
| Q28082757 | Evasion of inflammasome activation by microbial pathogens |
| Q40179129 | Evidence of treatment of chronic inflammation in childhood and adolescence with biologics |
| Q37800842 | Fevers and the Rheumatologist |
| Q26770209 | From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection |
| Q38528624 | From bench to bedside and back again: translational research in autoinflammation |
| Q37077793 | From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases |
| Q26776120 | Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure |
| Q51716028 | Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1β during acute allergic airway inflammation. |
| Q40252367 | Genetic fever syndromes. Hereditary recurrent (periodic) fever syndromes |
| Q38053858 | Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan |
| Q34142714 | Have we overestimated the benefit of human(ized) antibodies? |
| Q50357559 | Hearing loss in Muckle-Wells syndrome. |
| Q38043522 | How not to miss autoinflammatory diseases masquerading as urticaria. |
| Q34262561 | IL-1 blockade in autoinflammatory syndromes |
| Q37696955 | IL-1 pathways in inflammation and human diseases |
| Q63214372 | IL-1-Antagonisten |
| Q37702138 | IL-1: discoveries, controversies and future directions |
| Q84324600 | IL-1beta-targeted antibody approved for rare autoinflammatory disorders |
| Q30251741 | IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? |
| Q38074355 | IL-1β biological treatment of familial Mediterranean fever. |
| Q64040007 | Idiopathic Pericarditis-an Autoinflammatory Disease? |
| Q35190461 | Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind |
| Q37979861 | Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes |
| Q37979862 | Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. |
| Q38542409 | Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes |
| Q37273133 | In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes |
| Q37738096 | Inflammasome and IL-1beta-mediated disorders |
| Q93050768 | Inflammasome inhibitors: promising therapeutic approaches against cancer |
| Q36829403 | Inflammasome-Mediated Autoinflammatory Disorders |
| Q34431953 | Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study |
| Q44182155 | Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome |
| Q92172322 | Inhibitor of apoptosis proteins in human health and disease |
| Q37761419 | Innate immunity and rheumatoid arthritis |
| Q88781397 | Interleukin 1 receptor (IL-1R1) activation exacerbates toxin-induced acute kidney injury |
| Q47599422 | Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond |
| Q42412163 | Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer? |
| Q38993264 | Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome |
| Q35133812 | Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives |
| Q92636027 | Interleukin-1 blockade treatment decreasing cardiovascular risk |
| Q37986227 | Interleukin-1 gene polymorphisms and chronic periodontitis in adult whites: a systematic review and meta-analysis |
| Q24606766 | Interleukin-1 in the pathogenesis and treatment of inflammatory diseases |
| Q92700384 | Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes |
| Q42109190 | Interleukin-1β inhibitors for the treatment of cryopyrin-associated periodic syndrome |
| Q41928389 | International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. |
| Q37925070 | Intracellular sensing of microbes and danger signals by the inflammasomes |
| Q34681333 | Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer |
| Q51834131 | Investigational drugs in systemic vasculitis. |
| Q41934684 | Is the inflammasome a potential therapeutic target in renal disease? |
| Q85204858 | Is there any treatment for inflammatory amyloidosis? |
| Q39243858 | Juvenile idiopathic arthritis: management and therapeutic options |
| Q37773243 | Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer |
| Q56962731 | Kälteinduzierte Quaddeln und Angioödeme |
| Q38177270 | Licensing Adaptive Immunity by NOD-Like Receptors |
| Q57273753 | Lifelong urticaria and multiple unexplained systemic symptoms |
| Q47104503 | Live-attenuated vaccines in a cryopyrin-associated periodic syndrome patient receiving canakinumab treatment during infancy |
| Q34240472 | MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes |
| Q37874889 | Managing your patient with gout: a review of treatment options |
| Q64074554 | MicroRNA Post-transcriptional Regulation of the NLRP3 Inflammasome in Immunopathologies |
| Q34240460 | Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts |
| Q47248926 | Molecular genetic investigation, clinical features and response to treatment in 21 patients with Schnitzler's syndrome |
| Q33798590 | Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals |
| Q39301708 | Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient |
| Q38211947 | Monogenic autoinflammatory diseases |
| Q90744138 | Monogenic autoinflammatory diseases in adults - a challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment |
| Q37162157 | Monogenic autoinflammatory diseases: concept and clinical manifestations |
| Q37466515 | Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation |
| Q34489840 | Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis |
| Q37299354 | Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues |
| Q40230708 | Muckle-Wells cryopyrinopathy: complex phenotyping and response to therapy in a new multiplex kindred. |
| Q37941886 | Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory? |
| Q39458288 | Muckle-Wells syndrome: clinical perspectives. |
| Q40657289 | Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: a large database study |
| Q34254942 | Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation |
| Q84474094 | Mutations in the IL1RN locus lead to autoinflammation |
| Q35907763 | NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment |
| Q98177717 | NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword |
| Q28387817 | NLRP3 inflammasome activation induced by engineered nanomaterials |
| Q35045146 | NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. |
| Q37642879 | Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). |
| Q39863212 | New drugs approved in 2009 |
| Q37059551 | New insights into the nature of autoinflammatory diseases from mice with Nlrp3 mutations |
| Q33823177 | Nlrp3: an immune sensor of cellular stress and infection |
| Q51061979 | Novel NLRC4 Mutation Causes a Syndrome of Perinatal Autoinflammation With Hemophagocytic Lymphohistiocytosis, Hepatosplenomegaly, Fetal Thrombotic Vasculopathy, and Congenital Anemia and Ascites. |
| Q47644899 | OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. |
| Q40237271 | Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome |
| Q38038253 | Ocular manifestations of the autoinflammatory syndromes |
| Q40057989 | Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome |
| Q37358329 | Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation |
| Q97905633 | Overview of the rarest causes of fever in newborns: handy hints for the neonatologist |
| Q46049018 | P02-027 - Quality of life in CAPS treated by Canakinumab |
| Q57452740 | Pathophysiology of Sickle Cell Disease |
| Q37991471 | Pattern recognition receptors in immune disorders affecting the skin. |
| Q84794425 | Periodic Fever Syndromes |
| Q40346170 | Periodic fever syndrome and autoinflammatory diseases |
| Q38959923 | Periodic fevers and autoinflammatory syndromes in childhood |
| Q36644667 | Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody |
| Q53122163 | Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. |
| Q38291356 | Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children |
| Q38674213 | Pharmacological treatment options for cryopyrin-associated periodic syndromes |
| Q34274075 | Pharmacotherapy for uveitis: current management and emerging therapy |
| Q38015260 | Physical urticaria |
| Q33710807 | Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. |
| Q26771462 | Preclinical characterization and clinical development of ILARIS(®) (canakinumab) for the treatment of autoinflammatory diseases |
| Q35184223 | Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes |
| Q36375787 | Prolonged urticaria and fever in a toddler |
| Q38431249 | Protective and detrimental roles of inflammasomes in disease |
| Q39064225 | Protein inhibitor of acid deoxyribonucleases. Improved purification procedure and properties |
| Q44328410 | Quantitative analysis to guide orphan drug development |
| Q92508435 | Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger |
| Q48399830 | Rationale for IL-1beta-targeted therapy to minimize hypoxic-ischemic encephalopathy |
| Q39382198 | Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study |
| Q40212229 | Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome |
| Q38537504 | Recommendations for the management of autoinflammatory diseases. |
| Q40379845 | Recommendations on therapy using interleukin-1beta-blocking agents |
| Q38560502 | Redox distress and genetic defects conspire in systemic autoinflammatory diseases |
| Q38522837 | Regulating against the dysregulation: new treatment options in autoinflammation |
| Q37750913 | Regulation of inflammasome activity. |
| Q41659293 | Relative contribution of IL-1α, IL-1β and TNF to the host response to Mycobacterium tuberculosis and attenuated M. bovis BCG. |
| Q37848210 | Renal amyloidosis in children |
| Q58326117 | Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab |
| Q38091387 | Research progress on the NLRP3 inflammasome and its role in the central nervous system |
| Q91735391 | Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome |
| Q38993829 | Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease |
| Q41769940 | Rilonacept and canakinumab |
| Q35557377 | Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). |
| Q38450662 | Role of biologics in intractable urticaria |
| Q38095844 | Role of interleukin-1 inhibitors in the management of gout |
| Q92711301 | Roles of Inflammasomes in Inflammatory Kidney Diseases |
| Q33661359 | Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies |
| Q35623130 | Sensors of the innate immune system: their link to rheumatic diseases |
| Q52720398 | Subcutaneous administration of a Neutralizing IL-1β antibody prolongs limb allograft survival. |
| Q40338012 | Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-1β-monoclonal antibody |
| Q53842436 | Successful treatment with canakinumab of a paediatric patient with resistant Behçet's disease. |
| Q35468003 | Sudden cardiac arrest secondary to cardiac amyloidosis in a young woman with cryopyrin-associated periodic syndrome |
| Q40270754 | Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome |
| Q35907804 | Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study |
| Q36327767 | Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes |
| Q30251986 | Systemic amyloidosis |
| Q38843398 | Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens |
| Q35659928 | Systemic arthritis in children: a review of clinical presentation and treatment |
| Q35662883 | Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report |
| Q90566954 | Targeting NLRP3 Inflammasome Activation in Severe Asthma |
| Q38137848 | Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease |
| Q34167205 | Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation |
| Q38106621 | Targeting inflammasomes in rheumatic diseases |
| Q37901025 | Targeting of the innate immunity/inflammation as complementary anti-tumor therapies |
| Q26744359 | Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac Death |
| Q37270409 | The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases |
| Q91973492 | The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases |
| Q37848193 | The Eurofever Project: towards better care for autoinflammatory diseases |
| Q92579132 | The First Case Series of Cryopyrin-Associated Periodic Syndrome in Korea |
| Q90084199 | The IL-1 family of cytokines and receptors in rheumatic diseases |
| Q37676929 | The IL-1 family: regulators of immunity |
| Q39132605 | The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases. |
| Q37901519 | The NLRP3 inflammasome in health and disease: the good, the bad and the ugly |
| Q28242527 | The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response |
| Q37702149 | The NLRP3 inflammasome, a target for therapy in diverse disease states |
| Q38948602 | The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and the Rationale for Targeting Interleukin-1 Alpha |
| Q33785735 | The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. |
| Q38496586 | The autoinflammatory diseases: a fashion with blurred boundaries! |
| Q38967233 | The burgeoning field of innate immune-mediated disease and autoinflammation |
| Q28070297 | The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome |
| Q57160539 | The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders |
| Q26825459 | The emerging role of biotechnological drugs in the treatment of gout |
| Q37802305 | The emerging role of interleukin-1β in autoinflammatory diseases |
| Q37897494 | The emerging role of interleukin-1β in autoinflammatory diseases |
| Q92124367 | The emerging roles of inflammasome-dependent cytokines in cancer development |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q51786270 | The future of drug development: advancing clinical trial design. |
| Q84612714 | The importance of biologicals in the treatment of SoJIA |
| Q37800522 | The inflammasome regulatory pathway and infections: Role in pathophysiology and clinical implications |
| Q24613816 | The inflammasome: in memory of Dr. Jurg Tschopp |
| Q24304087 | The inflammasomes |
| Q42225483 | The inflammasomes in autoinflammatory diseases with skin involvement |
| Q34489972 | The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. |
| Q39443996 | The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation |
| Q38070133 | The role of inflammasome-derived IL-1 in driving IL-17 responses |
| Q92525889 | The role of inflammasomes in kidney disease |
| Q37957867 | The role of the NLRP3 inflammasome in gout |
| Q36903288 | The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. |
| Q37810218 | Therapeutic monoclonal antibody concentration monitoring: free or total? |
| Q35868028 | Therapy of autoinflammatory syndromes |
| Q35122583 | Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey |
| Q34088555 | Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance |
| Q36816872 | Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases |
| Q37636664 | Treating inflammation by blocking interleukin-1 in humans |
| Q26799747 | Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies |
| Q33767097 | Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens |
| Q38993330 | Treatment of systemic-onset juvenile arthritis with canakinumab |
| Q37642763 | Treatment strategies for juvenile idiopathic arthritis |
| Q98471241 | Triacylglycerol synthesis enhances macrophage inflammatory function |
| Q38004932 | Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. |
| Q40147920 | Unified Modeling of Familial Mediterranean Fever and Cryopyrin Associated Periodic Syndromes |
| Q38871098 | Unintended Immunological Consequences of Biologic Therapy. |
| Q64249669 | Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases |
| Q38071693 | Update on biologicals for treatment of juvenile idiopathic arthritis |
| Q38189469 | Urticaria mimickers in children |
| Q34607687 | Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes |
| Q39044487 | What do we know about the inflammasome in humans? |
| Q43805795 | What's new in internal medicine? |
| Q33833871 | Why not treat human cancer with interleukin-1 blockade? |
| Q33357128 | Working the endless puzzle of hereditary autoinflammatory disorders |
| Q84148894 | [CAPS treatment] |
| Q84148897 | [Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes] |
| Q84589751 | [Treatment of autoinflamatory diseases: which projections?] |